Arcus Biosciences [RCUS] vs Harmony Biosciences [HRMY] Detailed Stock Comparison
Arcus Biosciences
NYSE
Loading...
Harmony Biosciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Arcus Biosciences wins in 5 metrics, Harmony Biosciences wins in 11 metrics, with 1 ties. Harmony Biosciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Arcus Biosciences | Harmony Biosciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.67 | 10.45 | Arcus Biosciences |
| Price-to-Book Ratio | 2.23 | 2.41 | Arcus Biosciences |
| Debt-to-Equity Ratio | 23.68 | 22.43 | Harmony Biosciences |
| PEG Ratio | 0.04 | 0.04 | Tie |
| EV/EBITDA | -1.36 | 5.99 | Arcus Biosciences |
| Profit Margin (TTM) | -113.74% | 23.42% | Harmony Biosciences |
| Operating Margin (TTM) | -5.00% | 24.03% | Harmony Biosciences |
| EBITDA Margin (TTM) | N/A | 24.03% | N/A |
| Return on Equity | -50.34% | 27.58% | Harmony Biosciences |
| Return on Assets (TTM) | -18.69% | 14.10% | Harmony Biosciences |
| Free Cash Flow (TTM) | $-176.00M | $218.67M | Harmony Biosciences |
| 1-Year Return | -35.82% | -16.76% | Harmony Biosciences |
| Price-to-Sales Ratio (TTM) | 4.68 | 2.41 | Harmony Biosciences |
| Enterprise Value | $445.08M | $1.47B | Harmony Biosciences |
| EV/Revenue Ratio | 1.70 | 1.91 | Arcus Biosciences |
| Gross Profit Margin (TTM) | N/A | 80.97% | N/A |
| Revenue per Share (TTM) | $3 | $14 | Harmony Biosciences |
| Earnings per Share (Diluted) | $-3.14 | $3.10 | Harmony Biosciences |
| Beta (Stock Volatility) | 0.83 | 0.84 | Arcus Biosciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Arcus Biosciences vs Harmony Biosciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Arcus Biosciences | 0.17% | -5.50% | 19.13% | 23.21% | 18.76% | -23.86% |
| Harmony Biosciences | -3.08% | -10.00% | -8.68% | -2.82% | -3.60% | -7.01% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Arcus Biosciences | -35.82% | -55.56% | -47.49% | -34.55% | -34.55% | -34.55% |
| Harmony Biosciences | -16.76% | -26.12% | -3.60% | -10.03% | -10.03% | -10.03% |
News Based Sentiment: Arcus Biosciences vs Harmony Biosciences
Arcus Biosciences
News based Sentiment: POSITIVE
Arcus Biosciences delivered exceptional Q2 results, exceeding expectations significantly, and continues to advance its clinical programs with promising data. While insider selling and trading volatility exist, the overall narrative is positive, supported by analyst confidence and upcoming catalysts.
Harmony Biosciences
News based Sentiment: POSITIVE
While the Q2 earnings slightly missed expectations, Harmony Biosciences demonstrated continued progress with its pipeline, reaffirmed its full-year guidance, and maintained strong institutional support. The company's ambitious strategic vision and positive analyst ratings suggest a positive outlook for long-term growth, making September a relatively positive month for investors.
Performance & Financial Health Analysis: Arcus Biosciences vs Harmony Biosciences
| Metric | RCUS | HRMY |
|---|---|---|
| Market Information | ||
| Market Cap | $1.23B | $1.86B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 863,370 | 893,510 |
| 90 Day Avg. Volume | 794,177 | 646,440 |
| Last Close | $11.52 | $32.39 |
| 52 Week Range | $6.50 - $18.98 | $26.47 - $41.61 |
| % from 52W High | -39.30% | -22.16% |
| All-Time High | $49.10 (Nov 22, 2021) | $62.08 (Dec 05, 2022) |
| % from All-Time High | -76.54% | -47.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 3.10% | 0.16% |
| Quarterly Earnings Growth | 3.10% | 2.43% |
| Financial Health | ||
| Profit Margin (TTM) | -1.14% | 0.23% |
| Operating Margin (TTM) | -0.05% | 0.24% |
| Return on Equity (TTM) | -0.50% | 0.28% |
| Debt to Equity (MRQ) | 23.68 | 22.43 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.16 | $13.44 |
| Cash per Share (MRQ) | $8.56 | $9.83 |
| Operating Cash Flow (TTM) | $-339,000,000 | $259.38M |
| Levered Free Cash Flow (TTM) | $-113,000,000 | $197.81M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Arcus Biosciences vs Harmony Biosciences
| Metric | RCUS | HRMY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.67 | 10.45 |
| Forward P/E | -2.47 | 9.94 |
| PEG Ratio | 0.04 | 0.04 |
| Price to Sales (TTM) | 4.68 | 2.41 |
| Price to Book (MRQ) | 2.23 | 2.41 |
| Market Capitalization | ||
| Market Capitalization | $1.23B | $1.86B |
| Enterprise Value | $445.08M | $1.47B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.70 | 1.91 |
| Enterprise to EBITDA | -1.36 | 5.99 |
| Risk & Other Metrics | ||
| Beta | 0.83 | 0.84 |
| Book Value per Share (MRQ) | $5.16 | $13.44 |
Financial Statements Comparison: Arcus Biosciences vs Harmony Biosciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RCUS | HRMY |
|---|---|---|
| Revenue/Sales | $28.00M | $184.73M |
| Cost of Goods Sold | N/A | $31.99M |
| Gross Profit | N/A | $152.74M |
| Research & Development | $122.00M | $34.54M |
| Operating Income (EBIT) | $-122.00M | $56.25M |
| EBITDA | $-108.00M | $66.98M |
| Pre-Tax Income | $-112.00M | $57.18M |
| Income Tax | $0 | $11.62M |
| Net Income (Profit) | $-112.00M | $45.56M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RCUS | HRMY |
|---|---|---|
| Cash & Equivalents | $192.00M | $489.00M |
| Total Current Assets | $1.03B | $642.69M |
| Total Current Liabilities | $192.00M | $175.12M |
| Long-Term Debt | $48.00M | $158.18M |
| Total Shareholders Equity | $531.00M | $720.53M |
| Retained Earnings | $-1.24B | $47.78M |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RCUS | HRMY |
|---|---|---|
| Operating Cash Flow | $-128.00M | $36.44M |
| Capital Expenditures | $-1.00M | $-128,000 |
| Free Cash Flow | $-133.00M | $33.86M |
| Debt Repayment | N/A | $-3.75M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RCUS | HRMY |
|---|---|---|
| Shares Short | 9.83M | 4.33M |
| Short Ratio | 13.27 | 8.35 |
| Short % of Float | 0.14% | 0.16% |
| Average Daily Volume (10 Day) | 863,370 | 893,510 |
| Average Daily Volume (90 Day) | 794,177 | 646,440 |
| Shares Outstanding | 92.20M | 57.14M |
| Float Shares | 59.89M | 50.63M |
| % Held by Insiders | 0.35% | 0.11% |
| % Held by Institutions | 0.68% | 0.95% |
Dividend Analysis & Yield Comparison: Arcus Biosciences vs Harmony Biosciences
| Metric | RCUS | HRMY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |